Shelter Pharma (543963) Q4 25/26 earnings summary

Executive summary

• Audited standalone financial results for the half year and year ended March 31, 2026, were approved by the Board on May 28, 2026.

• Statutory auditors issued an unmodified opinion on the financial results.

• CA Ismail Ibrahimbhai Lakhani was reappointed as internal auditor for FY 2026-27.

Financial highlights

• Revenue from operations for FY 2025-26 was ₹7,313.36 lakh, up from ₹5,066.02 lakh in FY 2024-25.

• Net profit for FY 2025-26 was ₹902.72 lakh, compared to ₹723.74 lakh in the previous year.

• EPS for FY 2025-26 was ₹6.26, up from ₹5.16 in FY 2024-25.

• Total assets as of March 31, 2026, stood at ₹8,423.29 lakh, up from ₹4,833.55 lakh a year earlier.

• Net cash from operating activities was negative ₹1,248.01 lakh for FY 2025-26, compared to positive ₹542.28 lakh in FY 2024-25.

Outlook and guidance

• The company continues to focus on pharmaceutical manufacturing as its core segment.